Although our results indicate that specific IFN-γ and IL-2 cytokines are increased during severity, we hypothesize that their release is a consequence of a severe inflammatory scenario to avoid a fatal outcome, and could be used as a prognosis biomarker for clinical management of severe COVID-19 patients. The gene discussed is IFNG; the disease is COVID-19.